Search Follow us

Cantargia (CANT)

Business description

Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm First North in 2015. It is developing two antibodies against IL1RAP, CAN04 and CANxx. CAN04 is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer.

Stock data

Market cap.SEK913.4m
Last closeSEK13.80
High / Low (52 weeks)SEK16.2 / SEK5.2
Stock market listingOMX
Forecast net cash (SEKm)14.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(11)58.6163.4
Relative *(7.5)53.4174.6

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
ADL Bionatur Solutions Adocia
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Antibe Therapeutics Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
ASIT Biotech ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Avivagen
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences
BioLineRx BiondVax Pharmaceuticals
Bionomics Bionor Pharma
BioPorto Diagnostics Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Caladrius Biosciences Can-Fite BioPharma
CannTrust Holdings Capstone Therapeutics
Carmat CASI Pharmaceuticals
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Elbit Medical
Ellex Medical Lasers Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis EyeGate Pharmaceuticals
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genkyotex
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Heat Biologics Inc.
Heidelberg Pharma Herantis Pharma
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Immutep Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncology Venture
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics Ossur
OvaScience OWL
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Sierra Oncology Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals T‐cell cancer therapies
Targovax TearLab Corp
Tekmira Telix Pharmaceuticals
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology
Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2016A 0.0 (47.6) (47.5) (271.96) N/A N/A
2017A 0.0 (60.0) (60.3) (186.00) N/A N/A
2018E 0.0 (80.9) (80.2) (141.79) N/A N/A
2019E 0.0 (93.8) (93.5) (141.19) N/A N/A

Last updated on 07/06/2018

Latest research

Investment summary

Cantargia is developing two antibodies against IL1RAP, CAN04 and CANxx. CAN04 is currently being studied in a Phase I/II CANFOUR trial. The first part of the trial (Phase I) will focus on several solid tumours, while the second part (Phase II) will focus on NSCLC and pancreatic cancer. Results from the Phase I part of the trial are expected in mid-2018. Cantargia expects CAN04 to work through a dual mechanism of action: inhibition of IL-1 signaling and antibody-dependent cellular cytotoxicity (ADCC). Recent Novartis data publication from its six-year Phase III cardiovascular outcomes study in heart attack patients with canakinumab provides some validation to Cantargia’s plans, as it unexpectedly showed that the drug reduced lung cancer incidence and mortality.

Last updated on 21/06/2018

Industry outlook

Increasing the understanding of inflammation in malignant process now includes findings that cytokines are not only produced by the immune cells, but also cancer itself could produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in cancer management.

Last updated on 21/06/2018

Key management

Goran Forsberg, CEO

Company address

81 Medicon Village
Scheelevagen 2, Lund
SE-223
Sweden
+46 46 27 56 260
View website